Name: Pracinostat (SB939)
Price: 273.00 USD

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    Pracinostat, also known as SB939, is a potent and orally available inhibitor of histone deacetylase (HDAC) with a relatively stronger selectivity (more than 1000-fold) for class I, class II and class IV HDACs rather than class III HDACs. Pracinostat potently suppresses proliferation in a wide range of cancer cell lines, including colon cancer, ovarian cancer, prostate carcinomas, acute myeloid leukaemia (AML) and B cell lymphoma. Recent study results have shown that SB939 induces the accumulation of acetylated histone H3 (AcH3) and acetylated α-tubulin and increases the expression of the cyclin dependent kinase inhibitor p21 in cancer cells.
- Properties
  - Alternative Name
    
    SB-939, SB 939; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide
    
    CAS Number
    
    929016-96-6
    
    Molecular Formula
    
    C20H30N4O2
    
    Molecular Weight
    
    358.48
    
    Appearance
    
    A solid
    
    Purity
    
    98.89%
    
    Solubility
    
    insoluble in H2O; ≥11.4 mg/mL in DMSO; ≥24.8 mg/mL in EtOH with ultrasonic
    
    Storage
    
    Store at -20°C
    
    * For Research Use Only
- Reference
  - 1. Manna PR, Ahmed AU, et al. "Overexpression of the steroidogenic acute regulatory protein in breast cancer: Regulation by histone deacetylase inhibition." Biochem Biophys Res Commun. 2019 Feb 5;509(2):476-482. PMID:30595381
    2. Bagnall NH, Hines BM, et al. "Insecticidal activities of histone deacetylase inhibitors against a dipteran parasite of sheep, Lucilia cuprina." Int J Parasitol Drugs Drug Resist. 2017 Apr;7(1):51-60. PMID:28110187

Pracinostat (SB939)

Pracinostat (SB939)

Background

We Also Recommend

Belinostat (PXD101)

CUDC-907

PCI-24781 (CRA-024781)